A5036304447- Chronic Lymphocytic Leukemia Research
- Lung Cancer Diagnosis and Treatment
- Inflammatory Myopathies and Dermatomyositis
- Asthma and respiratory diseases
- Lung Cancer Treatments and Mutations
- Business Law and Ethics
- Neutropenia and Cancer Infections
- Allergic Rhinitis and Sensitization
- Total Knee Arthroplasty Outcomes
- Influenza Virus Research Studies
- Celiac Disease Research and Management
- Systemic Sclerosis and Related Diseases
- Spondyloarthritis Studies and Treatments
- Lung Cancer Research Studies
- Epilepsy research and treatment
- Gastric Cancer Management and Outcomes
- PI3K/AKT/mTOR signaling in cancer
- Early Childhood Education and Development
- Immune Response and Inflammation
- Inhalation and Respiratory Drug Delivery
- Liver Disease and Transplantation
- Vaccine Coverage and Hesitancy
- Medication Adherence and Compliance
- Nonmelanoma Skin Cancer Studies
- Helicobacter pylori-related gastroenterology studies
RTI Health Solutions
2016-2025
Triangle
2014-2024
Harris Health System
2023
Massachusetts General Hospital
2023
Harvard University
2023
GlaxoSmithKline (United Kingdom)
2002-2021
University of Bergen
2021
St Bartholomew's Hospital
2019
Kaiser Permanente
2019
University of Kent
2018
Background: There is a paucity of data on mortality and causes death (CoDs) in patients with sporadic inclusion body myositis (sIBM), rare, progressive, degenerative, inflammatory myopathy that typically affects those aged over 50 years.
Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancer MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved inhibitor, routine US practice. Materials & methods: Patient data were collected using retrospective medical record review, led by participating oncologists. Eligible initiated treatment capmatinib any line, after BM diagnosis, between May 2020 June 2021. Data on overall response rate (rwORR)...
ABSTRACT Background and Aims The severe alpha‐1 antitrypsin deficiency (AATD) genotype Pi*ZZ increases the risk of liver disease (AATD‐LD) lung disease. While non‐invasive tests (NITs) are widely used for fibrosis stage monitoring all diseases, consensus use in AATD‐LD is limited. A Delphi panel study was conducted to address this need. Method Healthcare providers who managed at least two patients with past years participated. Two iterative surveys were developed administered. second survey...
New adjuvant treatments are being developed for patients with resected non-small cell lung cancer (NSCLC). Due to scarcity of real-world data available treatment costs and resource utilization, health technology cost-effectiveness assessments can be limited. We estimated the burden cost-of-illness associated completely stage IB-IIIA NSCLC in France, Germany United Kingdom (UK).Eligible were aged ≥18 years between August 2009 July 2012. Patients (living or deceased) enrolled at clinical sites...
In patients with pro-opiomelanocortin (POMC) or leptin receptor (LEPR) deficiency, managing obesity and hyperphagia can be burdensome for caretakers. The impacts on health-related quality of life are under-recognized not well characterized. We conducted in-depth qualitative interviews in POMC (n = 3) LEPR 2) deficiencies participating an ongoing open-label extension phase 3 clinical trials the melanocortin 4 agonist setmelanotide to describe patient experience characterize changes following...
This study identified two potential novel biomarkers of peroxisome proliferation in the rat. Three proliferator-activated receptor (PPAR) ligands, chosen for their high selectivity towards PPARα, -δ and -γ subtypes, were given to rats twice daily 7 days at doses known cause a pharmacological effect or proliferation. Fenofibrate was used as positive control. Daily treatment with PPARα agonists produced liver hypertrophy. 1H nuclear magnetic resonance spectroscopy multivariate statistical data...
Induction of IFNα in the upper airways via activation TLR7 represents a novel immunomodulatory approach to treatment allergic asthma. Exploration 8-oxoadenine derivatives bearing saturated oxygen or nitrogen heterocycles N-9 substituent has revealed remarkable selective enhancement inducing potency series. Further was achieved with (S)-pentyloxy substitution at C-2 leading selection GSK2245035 (32) as an intranasal development candidate. In human cell cultures, compound 32 resulted...
Modulation of the airways' immune milieu is a key therapeutic goal for remission from respiratory allergies. To explore this hypothesis, GSK2245035, selective Toll-like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties, was developed intranasal application. Doses clinical assessment were extrapolated translational biomarker studies in primates. Randomized, double-blind, placebo-controlled trials healthy volunteers and patients allergic rhinitis...
To inform health-technology assessments of new adjuvant treatments, we describe treatment patterns in patients with complete resection stage IB-IIIA non-small cell lung cancer (NSCLC) France, Germany, and the United Kingdom (UK).Data were collected via medical record abstraction. Patients aged ≥18 years completely resected NSCLC, diagnosed between 01 January 2009 31 December 2011. Median follow-up was 26 months. Adjuvant clinical outcomes summarized descriptively.Among 831 studied, 239 (29%)...
The diagnostic utility of alpha-glutathione S-transferase ( αGST) in the assessment acute hepatotoxicity was compared with a range markers including alanine aminotransferas e (ALT) and aspartate (AST). Rats were given single oral dose either α-naphthylisothiocynate (ANIT), bromobenzen (BrB), or thioacetamide (TAM) at concentrations previously shown to induce marked hepatotoxicity. progression each hepatic lesion monitored by measurement battery markers, αGST, plasma collected time points...
Early diagnosis of ankylosing spondylitis (AS) remains challenging because the high prevalence chronic back pain in patients initially treated by nonrheumatology health care providers (HCPs). We assessed patient pathway to rheumatology referral, including HCP recognition inflammatory (IBP) and other features suggestive AS, diagnostic workup, treatment, referral a specialist with goal identifying barriers rheumatologist.US HCPs from 10 specialties were invited participate cross-sectional...
Optimization of a lead series PI3Kδ inhibitors based on dihydroisobenzofuran core led to the identification potent, orally bioavailable compound 19. Selectivity profiling 19 showed similar potency for class III PI3K, Vps34, and PI3Kδ, was not well-tolerated in 7-day rat toxicity study. Structure-based design an improvement selectivity over Vps34 and, focus oral phramacokinetics properties resulted discovery 41, which improved toxicological outcomes at exposure levels